Healthcare
Jade Biosciences, Inc.(JBIO)
Live Price
Offline$16.87
+8.63% today
1Y Change
+60.51%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $780.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +95.2%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Jade Biosciences, Inc. (JBIO) is a Healthcare stock with a market cap of $780.00M and listed on NASDAQ. The stock last traded around $16.87 and up 60.5% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +95.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +95.2%, free cash flow -33.3% with operating margin 0.0% and ROIC -28.1%. Stock Foundry combines JBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +95.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.2% | -2.8% | -36.4% |
2026 Mar 6, 2026 | +75.6% | +2.7% | -0.9% | +15.1% |
2025 Nov 13, 2025 | +15.8% | +10.5% | +18.6% | +54.8% |
Benchmark Edge
JBIO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JBIO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JBIO Max Drawdown
-44.21%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JBIO and SPY.
Company Overview
Jade Biosciences, Inc.
NASDAQ Global Market
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
- Leadership
- Tom Frohlich
- IPO Date
- Apr 29, 2025
- Employees
- 50
- Street Address
- 221 Crescent Street Building 23
- Mailing
- Waltham, MA, 02453
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 1 916-322-1700
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.1
Growth
- Revenue
- 0.0%
- EPS
- +95.2%
- Free Cash Flow
- -33.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -64.6%
- ROIC
- -28.1%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 20.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.